Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High- and low-dose radiotherapy plus PD-1 inhibitor and GM-CSF in advanced recurrent metastatic head and neck tumors
ChiCTR2300068958Phase 4Not yet recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sargramostim in Cervicofacial Cancer, nasopharyngeal carcinoma (NPC) and head and neck cancer (HNC), sponsored by Renmin Hospital of Wuhan University. Primary endpoint: Objective response rate. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
sargramostim
03
Conditions
Cervicofacial Cancernasopharyngeal carcinoma (NPC)head and neck cancer (HNC)
Beyond the preview
Go deeper on ChiCTR2300068958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068958.